Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvo’s Pennsaid May Need Additional Data Before Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Canadian firm says new Phase III studies will not be necessary for the “approvable” NSAID lotion.

You may also be interested in...



Nuvo Aiming For Fourth Quarter Response To Pennsaid “Approvable” Letter

Already agreed-upon studies should be concluded in time, but FDA could require more animal data for approval of the topical NSAID.

Nuvo Aiming For Fourth Quarter Response To Pennsaid “Approvable” Letter

Already agreed-upon studies should be concluded in time, but FDA could require more animal data for approval of the topical NSAID.

Nuvo's Pennsaid “Approvable” For Osteoarthritis

Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel